---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-008270"
form_type: "8-K"
ticker: "PAYS"
cik: "0001496443"
company_name: "Paysign, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:05:45.220997+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Paysign Q3 revenue $21.6M (+41.6% YoY); raises full-year 2025 guidance

## Summary
- Q3 2025 revenue $21.6M (+41.6% YoY); net income $2.22M (+54.2% YoY); diluted EPS $0.04 vs $0.03 YoY.
- Adjusted EBITDA $5.04M (23.3% margin), up 78.1% YoY; pharma patient affordability revenue surged 141.9% to $7.92M.
- Plasma revenue grew 12.4% to $12.86M; exited with 595 plasma centers (down 12 QoQ) and 105 active pharma programs (up 8 QoQ).
- Raises FY2025 guidance: revenue $80.5M–$81.5M (38.7% YoY midpoint), net income $7.0M–$8.0M, Adjusted EBITDA $19.0M–$20.0M.
- Ended quarter with $7.53M unrestricted cash, zero bank debt; opened new 30,000 sq ft customer service center.

## SEC filing metadata
- accession: 0001683168-25-008270
- form_type: 8-K
- ticker: PAYS
- cik: 0001496443
- company_name: Paysign, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1496443/000168316825008270/0001683168-25-008270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1496443/000168316825008270/paysign_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-008270
- JSON: https://secwatch.observer/filing/0001683168-25-008270.json
- Plain text: https://secwatch.observer/filing/0001683168-25-008270.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.